Theradiag 品牌介绍

浏览量：2837

Theradiag

品牌简介

由于我们在开发人员和营销人员方面拥有超过 25 年的经验，我们被公认为自身免疫和多路复用领域的主要领导者之一，拥有完整且不断发展的试剂系列.
Theradiag通过其体外诊断活动在70多个国家开展业务，并受益于治疗学的强劲增长，它汇集了一系列独特和创新的技能，为每个客户、生物学家和临床医生提供个性化的反应。Theradiag是治疗学和自身免疫性疾病监测领域的领导者，而自身免疫性疾病是世界第三大发病原因。
Theradiag的销售和营销业务分为两个主要活动：
–该“Theranotics”活动专门由内部研发的内部产品组成，为用于治疗自身免疫疾病和癌症的生物疗法提供个性化的药物解决方案；
–该“体外诊断”活动涵盖主要在自动免疫、过敏、传染病以及最近的肿瘤学和分子生物学领域的内部产品和分销产品。
治疗学，即应用于特定治疗的诊断学，为临床医生提供了控制生物技术药物疗效的手段，并为每位患者提供个性化治疗。

Established on the diagnostics market for 30 years, Theradiag is now recognized as a key player in the development, manufacturing and marketing of innovative in-vitro diagnostic products, but also as a pioneer in Theranostics. This extensive experience in the field of diagnostics, combined with the reliability of our products and the performance of our customer service, enable us to address biologists as a high-quality partner with ISO 13 485 certifications.

Present in more than 70 countries, through its in vitro diagnostic activities and benefiting from strong growth in Theranostics, Theradiag brings together a whole range of unique and innovative skills to provide a personalized response to each of its customers, biologists and clinicians. Theradiag is a leader in Theranostics and in the monitoring of autoimmune diseases, which is the third leading cause of morbidity in the world.

Theradiag’s sales and marketing operations are organized into two main activities:

– the “Theranostics” activity, which consists exclusively of in-house products developed through internal R&D, provides a personalized medicine solution for biotherapies used for treating auto-immune diseases and cancer;

– the “In-vitro Diagnostics” activity covers in-house products and distribution products mainly in the fields of auto-immunity, allergies, infectious diseases and, more recently, oncology and molecular biology.

Theranostics, diagnostics applied to a specific therapy, give clinicians the means to control the efficacy of drugs derived from biotechnology and to personalize treatments for each patient.

Theradiag has developed and received the CE Mark for Lisa Tracker, the world’s only comprehensive range of tests for monitoring the monoclonal antibodies used in the treatment of auto-immune and inflammatory diseases. Monitoring tests for cancer treatments such as Rituximab and Bevacizumab have recently enabled the range to be expanded to oncology, and new products are currently being developed to supplement this range. Lisa Tracker has seen buoyant growth in its activity in recent years thanks to its international marketing and to the publication of numerous studies demonstrating the clinical appeal of monitoring the treatments concerned.

For the last three years, in-vitro Diagnostics, Theradiag’s historical activity, has focused on developing products that have been designed and manufactured in house and innovative distribution products (molecular biology). Theradiag has recognized expertise in the diagnosis of auto-immune diseases with its multiplex test range (Technologie Luminex®) that covers the main auto-immune diseases.

Since its IPO at the end of 2012, Theradiag’s strategic reorientation, focusing on the development of proprietary kits and notably Theranostics, has allowed the Company to increase its profitability and is the cornerstone of its future development.

Main product